Sponsored Content

Supply Chain Security -- If Your API Supply Is Important, You Should Take Five Minutes To Read This

We all know that active pharmaceutical ingredient (API) end user supply chain security is a critical component to getting the finished dosage to market. Securing the supply chain means that discipline, diligence, expertise and compliance are...

Embarking Upon the Commercial Manufacturing Journey for a Biologic: Strategies to Achieve Successful Approval & Launch

In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey.

Build or Buy Challenge: Six Advantages of Using a Pre-Qualified, Fully Customizable GMP Environment

Today, biopharma companies face growing challenges when capacity is at a premium. Investment decisions must be made to ultimately determine the expansion of facilities, headcounts and technology choices necessary to maintain supply. Discover the...

The Role of cGMP Chemicals in Cell & Gene Therapies

Improvements in raw material inputs are necessary in order to deploy cell & gene therapies economically and at scale. Watch an on-demand webinar featuring Avantor experts to learn about challenges associated with using non-GMP raw materials, as...

Advancing Gene Therapy by Solving Challenges in Scale-Up & Manufacturing

Today’s biologic drugs give the promise of breakthrough treatment options for the world’s most challenging diseases and chronic conditions. In the case of gene therapies, the impact of these treatments will only expand as they are administered to...

New Choices to Help Improve mAbs Downstream Manufacturing Efficiency: Introducing the J.T.Baker® BAKERBOND® PROchievA™ Recombinant Protein A Resin

An integrated mAbs downstream purification process featuring Avantor J.T.Baker® BAKERBOND® PROchievA™ recombinant protein A chromatography columns and resins can enable significant throughput improvement while removing of critical impurities.

Small-Molecule Matters: Integration in Drug Development

How a collaborative approach between small and large drug developers with the right CDMO can overcome critical challenges to achieve greater efficiencies in quality, time, and cost – at every stage of the small molecule drug lifecycle.

COVID-19 and What’s Next for API Sourcing?

The pandemic challenged the global supply chain instantly. Geopolitical tensions and the call for localizations and self-reliance are further adding to the complexity of today’s API souring. In this article we look on supply chain security in a...

A Cambrex Webinar - Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh, discusses the importance of understanding crystallization processes to avoid unnecessary cost, risk and development delays.

Overcoming Challenges to Deliver Fixed Dose Combination (FDC) Drug Products

With Cambrex’s experience in combining two or more active pharmaceutical ingredients (APIs) into Fixed Dose Combination drugs (FDCs), we are the CDMO that’s expertly positioned to partner with you. Discover the benefits and challenges as we review...

Q&A with Stephan Haitz, President, CDMO Sales & Marketing at Cambrex

Stephan Haitz, President, CDMO Sales & Marketing discusses small molecule trends and how the CDMO industry is constantly evolving to meet the demands and needs of the growing clinical pipeline.

A Cambrex Webinar- De-Risking the Solid Form Landscape of an API

Dr. David Pearson, Chief Scientific Officer of Cambrex Edinburgh, discusses how a full understanding of the crystalline landscape of an active pharmaceutical ingredient (API) molecule can predict stability and solubility, minimizing...

Future focus: Our 2020 vision

Cambrex eBook: The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021, driven by positive industry trends — many of which our experts commented on in Part 1 of the Cambrex eBook. Market data shows just how...

Small Molecules: 2020 Vision

Cambrex experts have contributed more articles to our biggest eBook yet. The industry trend of outsourcing to CDMOs continues. With more services, capabilities, facilities and employees than ever before. Enjoy Part 1 of our latest Cambrex...

Digital Transformation in 2020: What Should Pharma Know?

To extract continuous value from R&D activities and ensure manufacturing quality, pharmaceutical companies are – or should be – embracing digital transformation. This business journey uses technology to turn fragmented systems into a harmonized...

A winning pediatric dosage formulation

When a global pharmaceutical company’s pediatric formulation and dosage form(s) didn’t fit the plant equipment profile used to manufacture the adult dosage form at the customer’s facility, they needed a high quality, agile CDMO with...

Page 1 of 2

Sponsored Content

Login Form